NCT00396916

Brief Summary

The purpose of the present study is to assess the role of hybrid PET/CT imaging diagnosis of active malignancy in cancer patients with rising tumor markers after treatment and in the diagnosis of primary tumor in patients with metastatic cancer of unknown origin. The clinical impact of PET/CT in the management and treatment of these two groups of cancer patients will be evaluated

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
45

participants targeted

Target at P25-P50 for not_applicable cancer

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2004

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

November 7, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 8, 2006

Completed
Last Updated

April 11, 2007

Status Verified

April 1, 2007

First QC Date

November 7, 2006

Last Update Submit

April 10, 2007

Conditions

Cancer

Keywords

cancer patients

Outcome Measures

Primary Outcomes (1)

  • the impact of the imaging modality on patient management

Secondary Outcomes (1)

  • the impact of the imaging modality on patient management

Interventions

PET/CT imagingDEVICE

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Cancer patients in complete remission after treatment, with serial elevation of serum tumor markers and negative CT or other conventional imaging test.
  • Patients with newly diagnosed metastatic cancer with unknown primary tumor
  • Glucose levels below 150-200
  • Patient signed informed consent

You may not qualify if:

  • Pregnant or lactating women
  • Patient unable or not willing to tolerate the test until its completion

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rambam Medical Center

Haifa, Israel

Location

MeSH Terms

Conditions

Neoplasms

Study Officials

  • Rachel Bar-Shalom, MD

    Rambam Health Care Campus

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 7, 2006

First Posted

November 8, 2006

Study Start

December 1, 2004

Last Updated

April 11, 2007

Record last verified: 2007-04

Locations

IL(1)